Get the app!
Back to Trades
Other3

Denali Therapeutics Inc.

DNLI

Total Value
$NaN

Company Information

Ticker Symbol
DNLI
CIK
0001714899

Insider Information

Role
Chief Medical Officer
Officer
Location
SOUTH SAN FRANCISCO, CA

Filing Details

Filing Date
Apr 20, 2026
Transaction Date
Apr 10, 2026
Accession Number
0001714899-26-000049
Form Type
3

Footnotes

  1. (F1)Includes 2,326 shares acquired under the Denali ESPP.
  2. (F2)Includes 145,845 Unvested RSU's.
  3. (F3)The shares subject to the option are fully vested and exercisable.
  4. (F4)25% of the shares subject to the option vested on January 3, 2024 and an additional 1/48 of the shares vested monthly thereafter.
  5. (F5)25% of the shares subject to the option vested on January 3, 2025 and an additional 1/48 of the shares vest monthly thereafter.
  6. (F6)25% of the shares subject to the option vested on January 3, 2026 and an additional 1/48 of the shares vest monthly thereafter.
  7. (F7)25% of the shares subject to the option will vest on January 3, 2027 and an additional 1/48 of the shares vest monthly thereafter.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.